Calcineurin inhibitors (CNIs) are the cornerstone of solid organ transplant immunosuppression and have transformed transplant outcomes since cyclosporine's introduction in the early 1980s. Both cyclosporine and tacrolimus act through the same downstream target, calcineurin, but bind distinct intracellular receptors, differ significantly in their potency and toxicity profiles, and require careful therapeutic drug monitoring to maintain the narrow therapeutic window between under-immunosuppression and over-immunosuppression.
Mechanism of Action: The Calcineurin-NFAT Pathway. When T lymphocytes recognize antigen through the T-cell receptor (TCR), intracellular calcium rises, activating the calcium-calmodulin complex that stimulates the serine-threonine phosphatase calcineurin. Calcineurin dephosphorylates the nuclear factor of activated T cells (NFAT), allowing NFAT to translocate from the cytoplasm into the nucleus, where it drives transcription of interleukin-2 (IL-2) and other T-cell activation genes. Cyclosporine binds cyclophilin (CyP), a cytoplasmic immunophilin, to form a cyclosporine-cyclophilin complex that inhibits calcineurin. Tacrolimus (also known as FK-506) binds a different immunophilin, FK-binding protein 12 (FKBP-12), forming a tacrolimus-FKBP-12 complex that also inhibits calcineurin. Both drug-immunophilin complexes block calcineurin's phosphatase activity, preventing NFAT dephosphorylation and nuclear translocation, thereby suppressing IL-2 transcription and halting T-cell activation and proliferation.1
Comparative Potency and Clinical Positioning. Tacrolimus is approximately 100-fold more potent than cyclosporine on a weight basis and has largely supplanted cyclosporine as the calcineurin inhibitor (CNI) of choice in most solid organ transplant protocols in high-income settings. In kidney, liver, heart, and lung transplantation, tacrolimus-based regimens consistently demonstrate superior acute rejection rates compared to cyclosporine-based regimens. Cyclosporine retains a role in some autoimmune indications including psoriasis, atopic dermatitis, and rheumatoid arthritis (RA) where its oral formulation and long-term safety data make it an option when other agents fail, and in bone marrow transplantation protocols. The selection between tacrolimus and cyclosporine in transplantation is driven primarily by efficacy differences, though their distinct toxicity profiles also factor into individualized decisions.12
Pharmacokinetics: Absorption. Both CNIs have highly variable oral bioavailability, which contributes substantially to the complexity of therapeutic drug monitoring. Cyclosporine oral bioavailability ranges from 20 to 50% and is formulation-dependent: the original oil-based formulation (Sandimmune) has erratic and food-dependent absorption, whereas the microemulsion formulation (Neoral, Gengraf) has more consistent but still variable absorption. Tacrolimus oral bioavailability averages 25% with a range of 5 to 67%, reflecting extensive first-pass metabolism. Both agents are highly lipophilic, are widely distributed into tissues, and cross the blood-brain barrier. Tacrolimus is additionally available in an extended-release once-daily formulation (Envarsus XR, Astagraf XL) that provides lower peak concentrations and is associated with reduced adverse effects in some studies. Food, particularly high-fat meals and grapefruit juice, significantly affects CNI absorption by modulating gastrointestinal P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) activity.2
Pharmacokinetics: Distribution, Metabolism, and Elimination. Both cyclosporine and tacrolimus are extensively bound in blood to erythrocytes and plasma proteins; cyclosporine distributes approximately 60% into erythrocytes, while tacrolimus distributes approximately 75 to 80% into erythrocytes, a point of essential importance for therapeutic drug monitoring because samples must be collected in whole blood (not plasma or serum) and processed consistently for accurate trough measurement. Both drugs are extensively metabolized by cytochrome P450 (CYP) 3A4 and CYP 3A5 (CYP3A5) in the liver and intestinal wall, with P-gp serving as an important efflux transporter affecting intestinal absorption and biliary excretion. CYP3A5 genetic polymorphisms are clinically relevant for tacrolimus: patients who express functional CYP3A5 (CYP3A5*1 allele carriers, approximately 50% of African American patients and 10 to 15% of European patients) require substantially higher tacrolimus doses to achieve target trough concentrations compared to CYP3A5 non-expressors. Both drugs are primarily eliminated through biliary excretion, with less than 1% appearing unchanged in urine; dose adjustment for renal impairment is not required on a pharmacokinetic basis, though both agents cause nephrotoxicity that limits their use as renal function declines.3
Therapeutic Drug Monitoring. Therapeutic drug monitoring (TDM) is mandatory for both CNIs because of their narrow therapeutic index and highly variable pharmacokinetics. Trough concentrations, designated C0 (pre-dose trough, drawn immediately before the morning dose), are the standard monitoring parameter for both drugs. For tacrolimus in kidney transplant, target troughs are typically 8 to 12 ng/mL in the early post-transplant period (first three months) and 5 to 8 ng/mL thereafter during maintenance. For cyclosporine, both trough (C0) and 2-hour post-dose monitoring (C2) are used; the C2 concentration is a better predictor of drug exposure than C0 for the microemulsion formulation, with target C2 values of 1,000 to 1,500 ng/mL at one month post-transplant declining to 600 to 800 ng/mL during maintenance. Samples must be collected in ethylenediaminetetraacetic acid (EDTA)-anticoagulated whole blood tubes and processed by validated immunoassay or liquid chromatography-tandem mass spectrometry (LC-MS/MS); the choice of assay affects measured concentrations, and institutional reference ranges should be specific to the analytical method used. All dose changes, formulation switches, co-medication changes involving CYP3A4 modifiers, and changes in gastrointestinal function should trigger repeat trough monitoring.23
Tacrolimus: Early (0–3 months): 8–12 ng/mL. Maintenance (>3 months): 5–8 ng/mL. Late (>1 year, stable): 4–6 ng/mL. Whole blood trough (C0), EDTA tube. CYP3A5 expressors require higher doses. Cyclosporine (microemulsion): C0 target: 200–300 ng/mL (early), 100–150 ng/mL (maintenance). C2 target: 1,000–1,500 ng/mL (early), 600–800 ng/mL (maintenance). Both: monitor renal function, blood pressure, magnesium, glucose, and complete blood count (CBC) at each clinical encounter.
The toxicity profiles of cyclosporine and tacrolimus overlap substantially because both act through calcineurin inhibition, but they differ in important ways that influence drug selection and monitoring. Both cause nephrotoxicity and increase infection risk; cyclosporine has a more pronounced metabolic and cosmetic profile, while tacrolimus causes more neurotoxicity and diabetes. Understanding these profiles is essential for managing transplant recipients and for safely prescribing CNIs in non-transplant autoimmune indications.
Nephrotoxicity: Mechanisms and Clinical Management. Calcineurin inhibitor (CNI)-induced nephrotoxicity is the dose-limiting toxicity of both agents and occurs through two distinct mechanisms. The first is acute functional nephrotoxicity: CNIs cause afferent arteriolar vasoconstriction in the kidney via increased endothelin and thromboxane production and decreased prostaglandin synthesis, reducing glomerular filtration rate (GFR) in a dose-dependent, reversible manner. This hemodynamic mechanism is responsible for the acute rise in serum creatinine seen within days to weeks of CNI initiation and responds to dose reduction. The second is chronic structural nephrotoxicity: prolonged CNI exposure causes irreversible interstitial fibrosis, tubular atrophy, and arteriolar hyalinosis, collectively termed CNI nephropathy. Chronic structural changes do not reverse with dose reduction and contribute to progressive chronic kidney disease (CKD) in long-term transplant recipients. The threshold cumulative exposure for structural damage is not well established, but minimization strategies using reduced CNI doses in combination with mycophenolate mofetil (MMF) are standard practice to limit this risk.4
Comparing CNI Nephrotoxicity: Cyclosporine vs. Tacrolimus. Head-to-head comparison studies suggest that tacrolimus and cyclosporine produce similar degrees of nephrotoxicity at equivalent immunosuppressive exposure, though some registry data indicate marginally superior renal outcomes with tacrolimus in kidney transplant recipients. Both agents cause hypertension, hypomagnesemia (through renal tubular magnesium wasting), and hyperuricemia (via reduced uric acid excretion, which may contribute to gout). Cyclosporine causes more severe and predictable hypertension, hyperlipidemia (elevated low-density lipoprotein, LDL), and hyperuricemia compared to tacrolimus. In contrast, tacrolimus is more diabetogenic: new-onset diabetes after transplantation (NODAT) occurs in 10 to 20% of patients receiving tacrolimus, compared to 5 to 10% with cyclosporine, likely because tacrolimus more potently impairs pancreatic beta-cell insulin secretion through its FKBP-12 (FK-binding protein 12) pathway. Hyperkalemia and metabolic acidosis from type 4 renal tubular acidosis (RTA) are more prominent with tacrolimus.4
Neurotoxicity and Other Adverse Effects. Neurotoxicity is significantly more common and more severe with tacrolimus than cyclosporine. Tacrolimus-induced neurotoxicity spans a spectrum from mild tremor (the most common manifestation, occurring in up to 40% of patients), headache, insomnia, and paresthesias at lower drug levels, to severe manifestations at supratherapeutic levels including seizures, posterior reversible encephalopathy syndrome (PRES), and acute psychosis. PRES is a neurological emergency characterized by headache, altered consciousness, seizures, and cortical visual disturbances with vasogenic edema visible on magnetic resonance imaging (MRI); it occurs in the context of hypertension, fluid overload, or CNI toxicity and resolves with dose reduction and blood pressure control. Cyclosporine also causes neurotoxicity including tremor and peripheral neuropathy but at lower frequency than tacrolimus. Both CNIs cause hirsutism and gingival hyperplasia, with cyclosporine being more notorious for both cosmetic effects; tacrolimus causes alopecia rather than hirsutism, which affects drug selection in some patients. Thrombotic microangiopathy (TMA), clinically presenting as hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP), is a rare but serious complication of both CNIs, caused by endothelial cell injury leading to microangiopathic hemolytic anemia, thrombocytopenia, and renal failure.4
Drug Interactions: Enzyme Inhibitors. The calcineurin inhibitors (CNIs) have among the most clinically significant drug interaction profiles of any class of therapeutic agents, driven by their metabolism through the cytochrome P450 3A4 enzyme (CYP3A4) and the related CYP3A5 isoform (CYP3A5) and transport by P-gp. Any drug that inhibits or induces these pathways will substantially alter CNI plasma concentrations, with potentially life-threatening consequences. Strong CYP3A4 inhibitors raise CNI concentrations and increase toxicity risk: the most important clinical interactions are with azole antifungals (fluconazole, itraconazole, voriconazole, posaconazole), which can raise tacrolimus or cyclosporine levels several-fold within days of coadministration and require pre-emptive CNI dose reduction of 30 to 60% with concurrent trough monitoring. Macrolide antibiotics (erythromycin, clarithromycin) are potent CYP3A4 inhibitors and raise CNI levels significantly; azithromycin has minimal CYP3A4 inhibitory activity and is safer in transplant recipients. The calcium channel blocker diltiazem and the antifungal itraconazole are sometimes deliberately co-prescribed with CNIs (particularly tacrolimus) to reduce drug cost by allowing lower CNI doses, a strategy that requires careful monitoring.6
CNI-Lowering Drug Interactions: Enzyme Inducers. Strong CYP3A4 and P-gp inducers dramatically reduce CNI exposure and risk acute rejection if not anticipated and managed. Rifampin (rifampicin) is the most clinically important example: coadministration with tacrolimus or cyclosporine reduces CNI area under the curve (AUC) by 70 to 90%, which can precipitate acute rejection within days. CNI doses must be increased 3 to 5-fold when rifampin is initiated, and concentrations must drop rapidly when rifampin is discontinued, requiring careful monitoring in both transitions. Other important inducers include rifabutin, rifapentine, carbamazepine, phenytoin, phenobarbital, and St. John's wort. Because of these interactions, treatment of tuberculosis (TB) in CNI-treated transplant patients requires careful substitution of rifampin with rifabutin wherever possible, or use of rifampin with aggressive CNI dose escalation guided by twice-weekly trough monitoring. Human immunodeficiency virus (HIV) antiretroviral interactions are complex and drug-specific, with protease inhibitors (ritonavir, cobicistat) being potent CYP3A4 inhibitors and NNRTIs (efavirenz, nevirapine) being inducers.6
Shared toxicities (both): Nephrotoxicity (functional + structural), hypertension, hypomagnesemia, hyperkalemia, hyperuricemia, increased infection risk, thrombotic microangiopathy (HUS/TTP, rare). Cyclosporine predominant: Hyperlipidemia (LDL elevation), hirsutism, gingival hyperplasia, more severe hypertension. Tacrolimus predominant: New-onset diabetes after transplant (NODAT, 10–20%), neurotoxicity (tremor, PRES, seizures at toxic levels), alopecia, more severe diabetogenicity. Drug interaction principle: any CYP3A4 or P-gp inhibitor or inducer requires immediate trough monitoring and dose adjustment; rifampin + CNI requires 3–5-fold dose increase and intensive monitoring.
The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus represent a mechanistically distinct immunosuppressive class that targets the proliferative response of T cells to cytokine stimulation rather than the initial activation signal. Their complementary mechanism of action relative to CNIs makes them valuable partners in combination regimens, though their distinct and sometimes serious toxicity profile requires careful patient selection and monitoring.
Mechanism of Action: mTORC1 Inhibition. Sirolimus (rapamycin) and everolimus are macrolide compounds that, like tacrolimus (formerly designated FK-506 in early research), bind to the intracellular immunophilin FKBP-12 (FK-binding protein 12). However, unlike tacrolimus, the sirolimus-FKBP-12 complex does not inhibit calcineurin; instead, it inhibits the mechanistic target of rapamycin complex 1 (mTORC1), a serine-threonine kinase that serves as the central integrator of nutrient, energy, and growth factor signals in cells. mTORC1 inhibition blocks the phosphorylation of its downstream effectors, ribosomal protein S6 (S6) kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), thereby suppressing protein synthesis required for cell cycle progression from the G1 (gap 1) to S phase. In the context of T-cell immunosuppression, mTOR inhibitors block the proliferative response to interleukin-2 (IL-2) and other cytokine growth signals, acting at a stage downstream of calcineurin. This mechanistic complementarity is the pharmacological rationale for calcineurin inhibitor (CNI)-mTOR inhibitor combination therapy: CNIs suppress IL-2 production (reducing the upstream signal), while mTOR inhibitors suppress the proliferative response to IL-2 (blocking the downstream response).7
Pharmacokinetics and Therapeutic Monitoring. Sirolimus has an exceptionally long half-life of approximately 60 hours, allowing once-daily dosing and steady-state achievement over 5 to 7 days; a loading dose of 6 mg is often used to accelerate therapeutic levels. Everolimus has a shorter half-life of approximately 28 to 30 hours and is dosed twice daily. Both drugs are extensively metabolized by cytochrome P450 3A4 (CYP3A4) and the related CYP3A5 (cytochrome P450 3A5) isoform and are substrates of P-gp, creating drug interaction profiles similar to those of the CNIs. Both require therapeutic drug monitoring. Sirolimus whole blood trough targets in kidney transplant maintenance range from 4 to 12 ng/mL depending on the degree of concomitant CNI use; when used as CNI replacement (conversion), higher troughs of 12 to 20 ng/mL are often targeted. Everolimus troughs in combination with reduced-dose CNI regimens are typically targeted at 3 to 8 ng/mL. Drug-drug interactions mirror those of tacrolimus and cyclosporine, with azole antifungals substantially increasing mTOR inhibitor levels and rifampin dramatically reducing them.78
Combination Rationale with CNIs: Complementarity and CNI Minimization. The principal clinical rationale for mTOR inhibitor use in transplantation is CNI minimization. Combining a reduced-dose CNI with an mTOR inhibitor maintains adequate immunosuppressive efficacy while reducing cumulative CNI nephrotoxicity, a strategy supported by several randomized controlled trials demonstrating superior renal function at 12 to 24 months in mTOR inhibitor-based CNI minimization regimens compared to standard CNI regimens.5 Early complete CNI elimination with conversion to mTOR inhibitor monotherapy is more challenging and associated with higher rejection rates. Practically, the combination of tacrolimus (at reduced target troughs of 3 to 5 ng/mL) plus everolimus is a well-established CNI-sparing protocol that maintains adequate immunosuppression while reducing cumulative CNI nephrotoxicity.8
Toxicity Profile of mTOR Inhibitors. The toxicity profile of sirolimus and everolimus differs in clinically meaningful ways from that of CNIs. Pulmonary toxicity is the most serious adverse effect unique to the mTOR inhibitor class: sirolimus-induced pneumonitis occurs in 3 to 11% of patients and ranges from asymptomatic radiographic infiltrates to severe organizing pneumonia or alveolar hemorrhage requiring drug discontinuation. The mechanism involves mTOR inhibitor effects on immune cell trafficking and cytokine production in the lung. Any new respiratory symptoms in a patient on an mTOR inhibitor must prompt chest imaging and consideration of drug discontinuation. Impaired wound healing is a clinically critical toxicity relevant to surgical timing: mTOR inhibitors inhibit fibroblast proliferation and reduce collagen deposition, increasing the risk of wound dehiscence, lymphocele, and incisional hernia. For this reason, mTOR inhibitors are typically avoided in the immediate post-operative period (first 4 to 12 weeks after transplant or any major surgery). Metabolic toxicities include hyperlipidemia (particularly hypertriglyceridemia, which is more severe with mTOR inhibitors than with CNIs), peripheral edema (often significant), and oral mucositis. mTOR inhibitors do not cause nephrotoxicity per se but impair renal recovery when used with CNIs at standard doses. New-onset diabetes after transplantation (NODAT) is less common with mTOR inhibitors than with tacrolimus.78
Pneumonitis: Class-specific; any new respiratory symptoms require chest CT and consideration of drug discontinuation. Bronchoalveolar lavage may be needed to exclude infection. Wound healing impairment: Avoid mTOR inhibitors for 4–12 weeks after transplant surgery and major operations; conversion to mTOR inhibitor-based regimen should be delayed until surgical healing is complete. Hypertriglyceridemia: More severe than with CNIs; treat with fenofibrate (preferred) or statin; avoid gemfibrozil (increases sirolimus levels). Peripheral edema: Often requires diuretic management. Oral mucositis: Reduce dose or switch to alternative; topical steroid mouth rinses may help. mTOR inhibitors are CYP3A4/P-gp substrates; azole antifungal and rifampin interactions are as significant as with CNIs.
Antimetabolites act by depleting the nucleotide precursors required for lymphocyte deoxyribonucleic acid (DNA) synthesis and proliferation. Azathioprine was the first effective immunosuppressant in clinical transplantation (introduced in the 1960s), but has been largely supplanted by mycophenolate mofetil (MMF) in most transplant indications due to MMF's superior efficacy and more favorable hematological safety profile. Both remain in use across transplant and autoimmune disease contexts.
Azathioprine: Mechanism and Thiopurine Metabolism. Azathioprine is a prodrug that is cleaved non-enzymatically to 6-mercaptopurine (6-MP), which undergoes further metabolism along three competing pathways. The anabolic pathway converts 6-MP to thioguanine nucleotides (TGNs) via hypoxanthine-guanine phosphoribosyltransferase (HGPRT); TGNs are the active immunosuppressive metabolites that incorporate into DNA, causing strand breaks and inhibiting purine synthesis. The catabolic pathway converts 6-MP to inactive thiouric acid via xanthine oxidase (XO); drugs that inhibit XO, particularly allopurinol and febuxostat (used for gout), block this catabolic pathway and dramatically increase thioguanine nucleotide (TGN) levels, causing severe, potentially fatal myelosuppression. Coadministration of azathioprine with allopurinol is absolutely contraindicated unless the azathioprine dose is reduced by 67 to 75%. A third enzyme, thiopurine methyltransferase (TPMT), methylates 6-MP to the inactive metabolite 6-methylmercaptopurine (6-MMP); high TPMT activity shunts drug away from the active TGN pathway.9
TPMT Pharmacogenomics and Clinical Implications. TPMT activity is governed by common polymorphisms in the TPMT gene, with population frequencies that differ by ancestry. Approximately 89 to 94% of individuals are homozygous for the wild-type high-activity allele (TPMT*1/*1) and metabolize azathioprine normally. Approximately 6 to 11% are heterozygous carriers of a low-activity variant allele (TPMT*3A being the most common in European populations, with TPMT*3C more prevalent in Asian and African populations), resulting in intermediate TPMT activity and requiring dose reduction of approximately 30 to 50%. Approximately 0.3% of individuals are homozygous for low-activity or absent-activity alleles (TPMT-deficient), with severely reduced or absent TPMT activity; these patients accumulate TGNs to toxic levels and develop profound, potentially fatal myelosuppression at standard azathioprine doses. TPMT genotyping or phenotyping before initiating azathioprine is now recommended by the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the Dutch Pharmacogenomics Working Group (DPWG). An alternative pharmacogenomic consideration is nudix hydrolase 15 (NUDT15) polymorphisms, which are more prevalent in Asian populations and also predict thiopurine-induced myelotoxicity; NUDT15 testing is recommended particularly in patients of East Asian or Southeast Asian ancestry.910
Mycophenolate Mofetil: Mechanism and Pharmacokinetics. Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed in the gut and liver to mycophenolic acid (MPA), the active compound. MPA inhibits inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo purine synthesis pathway. Lymphocytes are uniquely dependent on the de novo purine synthesis pathway for DNA synthesis (unlike most other cell types, which can use the salvage pathway), making IMPDH inhibition selectively immunosuppressive for lymphocytes. MPA is glucuronidated in the liver to the inactive metabolite mycophenolic acid glucuronide (MPAG), which undergoes enterohepatic recirculation; MPAG is excreted into bile, deconjugated by gut flora, and reabsorbed as MPA, contributing a secondary peak in MPA plasma concentrations at 6 to 12 hours after dosing. Enteric-coated mycophenolate sodium (Myfortic) is an alternative formulation that releases MPA in the duodenum rather than the stomach and may reduce upper gastrointestinal (GI) adverse effects, though the overall GI tolerability benefit compared to MMF is modest.11
MMF Clinical Use and Toxicity. Mycophenolate mofetil (MMF) is used at a standard dose of 1 to 1.5 g twice daily (2 to 3 g/day) in kidney transplant and at similar doses in heart, liver, and lung transplantation. Therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) is possible but less routinely performed than for CNIs; MPA 12-hour area under the curve (AUC0-12) targets of 30 to 60 mg/hour/L correlate with efficacy and toxicity. The principal toxicities are gastrointestinal and hematological. Gastrointestinal (GI) adverse effects occur in 30 to 45% of patients and include nausea, vomiting, diarrhea, abdominal cramping, and less commonly peptic ulceration; GI symptoms are dose-dependent and often improve with dose reduction, twice-daily rather than three-times-daily dosing, or switch to the enteric-coated formulation. Myelosuppression, particularly leukopenia and thrombocytopenia, occurs with MMF but is less severe than with azathioprine.11
MMF Teratogenicity and Contraception Requirements. MMF is a potent human teratogen and is absolutely contraindicated in pregnancy: it causes cleft palate, microtia (ear abnormalities), limb hypoplasia, and cardiac defects in up to 25% of exposed pregnancies and is classified as a known teratogen under the US Food and Drug Administration (FDA) Pregnancy and Lactation Labeling Rule (PLLR). All women of childbearing potential must use reliable contraception during MMF therapy; the manufacturer requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program for new prescriptions. Azathioprine, though not entirely risk-free in pregnancy, is considered a safer alternative when maintenance immunosuppression is required during pregnancy and is the preferred antimetabolite for transplant recipients planning conception.1112
Allopurinol and febuxostat inhibit xanthine oxidase (XO), the primary catabolic pathway for 6-mercaptopurine (6-MP). Coadministration with azathioprine at standard doses causes 4-fold accumulation of thioguanine nucleotides (TGNs), resulting in severe myelosuppression (pancytopenia) that can be fatal. If gout management requires XO inhibitor use in a patient on azathioprine: reduce azathioprine dose by 67–75% AND monitor CBC weekly for the first 4 weeks, then monthly. Alternative: switch immunosuppressant to MMF, or use a uricosuric agent (probenecid) for gout instead. Colchicine and NSAIDs do not interact with azathioprine. This interaction requires active management in transplant patients with hyperuricemia, which is common due to CNI use.
Corticosteroids remain an essential component of transplant immunosuppression protocols, both for acute rejection prevention in the early post-transplant period and for treatment of acute rejection episodes. Their pleiotropic anti-inflammatory effects arise from genomic mechanisms targeting transcriptional regulation, and their toxicity profile drives active efforts toward steroid minimization and withdrawal in stable long-term recipients.
Molecular Mechanisms: Genomic Actions. Corticosteroids exert their immunosuppressive effects primarily through the intracellular glucocorticoid receptor (GR), a ligand-activated transcription factor. After binding corticosteroid, the GR-ligand complex translocates to the nucleus, where it modulates gene expression through two principal mechanisms. In transactivation, the GR dimer binds glucocorticoid response elements (GREs) in gene promoters to directly activate transcription of anti-inflammatory genes including lipocortin-1 (annexin-1 (A1), which inhibits phospholipase A2 and thereby reduces arachidonic acid release), interleukin-10 (IL-10), and the inhibitor of nuclear factor kappa B (IkB). In transrepression, the GR interacts directly with activated transcription factors nuclear factor kappa B (NF-kB) and activator protein 1 (AP-1) without deoxyribonucleic acid (DNA) binding, blocking their transcriptional activity; this mechanism suppresses transcription of numerous pro-inflammatory genes including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), interleukin-8 (IL-8), cyclooxygenase-2 (COX-2), and intercellular adhesion molecule 1 (ICAM-1). Transrepression of NF-kB and AP-1 accounts for much of the clinical anti-inflammatory effect of corticosteroids. Non-genomic mechanisms, including rapid effects on membrane signaling and mitochondrial function, also contribute at higher doses.13
Corticosteroids in Transplant Protocols. In solid organ transplantation, high-dose corticosteroids (methylprednisolone 500 mg to 1 g intravenously perioperatively) are universally used at the time of transplantation and for treatment of acute cellular rejection (pulse steroids). Maintenance oral prednisone doses are then tapered over weeks to months following transplant. Standard maintenance doses range from 5 to 10 mg prednisone daily, though many programs taper to 0 to 5 mg daily or pursue steroid withdrawal by 6 to 12 months post-transplant in stable, low-immunological-risk recipients. Steroid-free protocols using alemtuzumab, anti-thymocyte globulin (ATG), or basiliximab induction allow early steroid withdrawal in selected patients, but are associated with higher rates of subclinical rejection in some registry analyses. Acute cellular rejection is treated with pulse intravenous methylprednisolone 250 to 1,000 mg for 3 to 5 consecutive days, with resolution of rejection in 60 to 90% of cases depending on rejection grade and timing.1314
Cumulative Toxicity and Steroid-Sparing Strategies. The cumulative toxicity of long-term corticosteroid use is the principal driver of steroid minimization strategies in transplantation. Major toxicities include osteoporosis and avascular necrosis of bone (particularly the femoral head), new-onset diabetes mellitus or worsening of pre-existing diabetes, hypertension, hyperlipidemia, cataracts, glaucoma, weight gain and cushingoid features, adrenal suppression, impaired wound healing, and increased susceptibility to infection. Osteoporosis prevention with calcium (1,000 to 1,200 mg/day), vitamin D (800 to 1,000 IU/day), and bisphosphonate therapy (for patients on long-term steroids with reduced bone density) is standard of care. Avascular necrosis occurs in up to 15% of patients on long-term corticosteroids, most commonly affecting the femoral head. Any transplant recipient reporting hip, shoulder, or knee pain should have magnetic resonance imaging (MRI) performed to exclude avascular necrosis, as early diagnosis allows core decompression to preserve the joint. Adrenal suppression develops with doses of prednisone greater than 5 mg/day for more than 3 to 4 weeks and persists for months to over a year after corticosteroid discontinuation; transplant recipients requiring surgery or experiencing physiological stress need supplemental corticosteroid coverage (stress-dose steroids) to prevent adrenal crisis.13
Corticosteroids in Non-Transplant Autoimmune Disease. Outside the transplant setting, corticosteroids are the most widely used immunosuppressants across rheumatology, dermatology, pulmonology, gastroenterology, and nephrology. Low-dose prednisone (5 to 7.5 mg/day) is used for maintenance in systemic lupus erythematosus (SLE), vasculitis, and inflammatory arthritis. Moderate doses (20 to 40 mg/day prednisone equivalent) are used for flares. High doses (1 mg/kg/day prednisone equivalent) are used for severe autoimmune conditions including polymyositis, dermatomyositis, and autoimmune hepatitis. Pulse methylprednisolone (1 g/day intravenously for 3 days) is used for organ- or life-threatening manifestations. Steroid-sparing agents, particularly azathioprine, mycophenolate mofetil (MMF), and methotrexate, are introduced early to allow corticosteroid dose reduction once disease is controlled; the universal therapeutic goal is to taper steroids to the lowest effective dose, ideally below 5 to 7.5 mg prednisone/day, and eventually discontinue if possible.13
Bone protection: calcium 1,000–1,200 mg/day + vitamin D 800–1,000 IU/day for all patients on steroids; add bisphosphonate for patients with bone loss or high fracture risk (DXA scan at baseline and every 1–2 years). Avascular necrosis: any hip, shoulder, or knee pain → MRI (plain radiograph insensitive early). New-onset diabetes: fasting glucose at each visit; HbA1c every 3 months if glucose impaired. Adrenal suppression: patients on >5 mg/day prednisone for >4 weeks need stress-dose steroids for surgery (hydrocortisone 50–100 mg IV at induction, then every 8 hours for 24–48 hours). Cataracts: annual ophthalmology referral for long-term steroid users. Infection: pneumocystis prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) for all transplant recipients regardless of steroid dose.
Effective transplant immunosuppression requires integrating multiple drug classes with complementary mechanisms to prevent rejection while minimizing cumulative toxicity. Modern protocols are organized into induction therapy (intensive immunosuppression at the time of transplant to prevent early acute rejection), maintenance therapy (ongoing immunosuppression to prevent rejection during the life of the graft), and treatment therapy (for established rejection episodes). Understanding the pharmacological rationale of each phase and the distinction between cellular and antibody-mediated rejection is essential for clinical practice.
Standard Triple Therapy Maintenance Protocols. The backbone of maintenance immunosuppression in solid organ transplantation consists of three mechanistically complementary agents: a CNI (almost always tacrolimus in contemporary practice), an antimetabolite (almost always MMF), and a corticosteroid (prednisone, usually at low maintenance doses). Each drug class targets a distinct step in T-cell activation and proliferation: the CNI blocks calcineurin-mediated nuclear factor of activated T cells (NFAT) activation and interleukin-2 (IL-2) transcription; MMF blocks the proliferative response to IL-2 by depleting purine precursors via inosine monophosphate dehydrogenase (IMPDH) inhibition; and corticosteroids suppress the cytokine environment and co-stimulatory signals required for effective T-cell activation. The three-drug combination provides synergistic immunosuppression at doses lower than would be required for any single agent to achieve adequate efficacy alone, reducing the cumulative toxicity of each component. CNI-sparing protocols substitute an mTOR inhibitor for part or all of the CNI, with the goals of preserving renal function and avoiding CNI nephropathy.14
Acute Cellular Rejection: Recognition and Treatment. Acute cellular rejection (ACR) is mediated by recipient T cells recognizing donor alloantigens on transplanted organ cells directly (via direct allorecognition, in which recipient T cells recognize intact donor major histocompatibility complex (MHC) molecules on donor antigen-presenting cells) or indirectly (via indirect allorecognition, in which recipient T cells recognize processed donor peptides presented on recipient MHC molecules). In kidney transplantation, ACR typically presents in the first 3 to 12 months post-transplant with rising serum creatinine, reduced urine output, hypertension, and graft tenderness; many cases are subclinical and diagnosed only on surveillance biopsy. Diagnosis requires allograft biopsy with classification according to the Banff criteria, which grade tubulointerstitial rejection (Banff I), vascular rejection (Banff II), and severe rejection (Banff III). Treatment of Banff I and early Banff II ACR is pulse intravenous methylprednisolone 250 to 1,000 mg daily for 3 to 5 days. Steroid-resistant rejection (failure to respond to pulse steroids within 3 to 5 days) is treated with lymphocyte-depleting antibody therapy (polyclonal anti-thymocyte globulin, ATG).1415
Antibody-Mediated Rejection: Pathophysiology and Management. Antibody-mediated rejection (AMR), also termed humoral rejection, is mediated by recipient immunoglobulin G (IgG) antibodies directed against donor human leukocyte antigens (HLAs) or other endothelial antigens (donor-specific antibodies, DSAs). DSAs bind to endothelial cells in the transplanted organ, activate complement (particularly the lectin and classical pathways), and recruit natural killer (NK) cells via Fc receptor-mediated antibody-dependent cellular cytotoxicity (ADCC). The Banff criteria for AMR require evidence of DSAs, characteristic histological changes (microvascular inflammation, peritubular capillary basement membrane multilayering, transplant glomerulopathy), and complement split product C4d deposition in peritubular capillaries. AMR is more difficult to treat than ACR and is the leading cause of late kidney allograft failure. Treatment of acute AMR includes plasmapheresis (to remove circulating DSAs), intravenous immunoglobulin (IVIG) at 2 g/kg to modulate anti-donor immune responses, and rituximab (to deplete DSA-producing B cells); outcomes are significantly worse than for ACR. Chronic active AMR is the dominant cause of late graft loss and has no proven effective treatment once established.15
Induction Agents: Basiliximab. Induction immunosuppression consists of intensive agents administered at and around the time of transplant to reduce the risk of early acute rejection. Basiliximab is a chimeric anti-IL-2 receptor alpha chain (anti-CD25) monoclonal antibody that blocks IL-2-mediated T-cell proliferation by competitively antagonizing IL-2 binding to its high-affinity receptor. It is administered as two fixed doses (20 mg intravenously on day 0 and day 4 post-transplant) and saturates the IL-2 receptor for approximately 4 to 6 weeks. Basiliximab is well tolerated with minimal adverse effects and is the standard induction agent in standard immunological risk kidney transplant recipients.14
Anti-Thymocyte Globulin. Anti-thymocyte globulin (ATG), available as equine preparation (ATGAM) and rabbit preparation (rATG, thymoglobulin), is a polyclonal antibody directed against multiple T-cell surface antigens including CD3 (the TCR signaling component), CD4 (helper T-cell co-receptor), CD8 (cytotoxic T-cell co-receptor), CD25 (the IL-2 receptor alpha chain), CD28 (co-stimulatory receptor), CD45 (common leukocyte antigen), and additional T-cell surface antigens. ATG causes profound and prolonged lymphocyte depletion through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), and is used in high-immunological-risk recipients and for treatment of steroid-resistant acute rejection. Adverse effects include cytokine release syndrome (fever, rigors, hypotension during infusion, managed by pre-medication with corticosteroids, antihistamines, and acetaminophen), leukopenia, thrombocytopenia, and increased risk of post-transplant lymphoproliferative disorder (PTLD) and opportunistic infections, particularly cytomegalovirus (CMV).1415
Standard-risk induction: Basiliximab 20 mg IV day 0 and day 4. High-risk induction: rATG (thymoglobulin) 1.5 mg/kg/day IV for 3–7 days; pre-medicate for cytokine release syndrome. Maintenance triple therapy: Tacrolimus (target trough 8–12 ng/mL early, 5–8 ng/mL maintenance) + MMF 1–1.5 g twice daily + prednisone taper to 5–10 mg/day by 3–6 months. Acute cellular rejection: Pulse methylprednisolone 250–1,000 mg IV daily ×3–5 days. Steroid-resistant ACR: rATG. Acute AMR: Plasmapheresis + IVIG (2 g/kg) + rituximab. Prophylaxis required in all transplant recipients: TMP-SMX (Pneumocystis jirovecii), valganciclovir (CMV in high-risk D+/R−), antifungal prophylaxis per protocol.
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-2729.
doi:10.1056/NEJMra033540Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48(1):88-112.
doi:10.3109/03602532.2016.1151037Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623-653.
doi:10.2165/00003088-200443100-00001Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481-508.
doi:10.2215/CJN.04800908Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-2575.
doi:10.1056/NEJMoa067411Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006;28(1):39-44.
doi:10.1097/01.ftd.0000183385.27394.e7Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3 Suppl):7S-14S.
doi:10.1016/s0041-1345(03)00211-2Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients. Transplantation. 2009;87(2):233-242.
doi:10.1097/TP.0b013e3181927a41Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenomics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes. Clin Pharmacol Ther. 2019;105(5):1095-1105.
doi:10.1002/cpt.1304Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235-1242.
doi:10.1200/JCO.2014.59.4671Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118.
doi:10.1016/s0162-3109(00)00188-0European Medicines Agency. Mycophenolate mofetil: pregnancy prevention programme. EMA/178644/2015. 2015. Available at: ema.europa.eu.
ema.europa.eu/mycophenolate-referralRhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.
doi:10.1056/NEJMra050541Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1-S155.
doi:10.1111/j.1600-6143.2009.02834.xHaas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307.
doi:10.1111/ajt.14625